Article
Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.
Bioscience reports - 1 Aug 2012
Yuen Hiu-Fung, Abramczyk Olga, Montgomery Grant, Chan Ka-Kui, Huang Yu-Han, Sasazuki Takehiko, Shirasawa Senji, Gopesh Srivastava, Chan Kwok-Wah, Fennell Dean, Janne Pasi, El-Tanani Mohamed, Murray James T
Abstract excerpt
Inhibition of the PI3K (phosphoinositide 3-kinase)/Akt/mTORC1 (mammalian target of rapamycin complex 1) and Ras/MEK [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase]/ERK pathways for cancer therapy has been pursued for over a decade with limited success. Emerging data have indicated that only discrete subsets of cancer patients have favourable responses to these...
Topics
- Apoptosis
- Benzamides
- Cell Line, Tumor
- Cell Survival
- Drug Synergism
- Feedback, Physiological
- Furans
- Humans
- MAP Kinase Signaling System
- Mechanistic Target of Rapamycin Complex 1
